Neurobiology of sleep and circadian rhythmsFeb 18, 2026

Alzheimer's disease as a timing problem: disrupted daily rhythms in brain support cells, waste removal, and treatment response

Circadian Biology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

This review reframes Alzheimer's disease as a systems-level timing disorder that may connect circadian disruption with glial dysfunction, impaired brain clearance, therapeutic response, and biomarker variability.

Evidence

It is a conceptual review synthesizing evidence on circadian clocks, sleep-wake rhythms, glial immunometabolism, aquaporin-4 polarity, glymphatic-lymphatic clearance, blood-brain barrier transport, and brain-to-blood signal export in Alzheimer's disease.

Caveat

Because the paper advances an integrative framework rather than testing an intervention or cohort endpoint, its chrono-therapeutic and biomarker implications remain hypothesis-generating.

Simplified

Alzheimer's disease (AD) is traditionally conceptualized as a disorder of protein aggregation and neurodegeneration, yet growing evidence indicates that fundamental temporal organization of brain physiology is also disrupted. In the healthy brain, circadian clocks coordinate sleep-wake behavior, glial immunometabolism, astrocytic aquaporin-4 polarity, and glymphatic-lymphatic clearance, aligning immune readiness and proteostasis with daily activity-rest cycles. In AD, this temporal coordination progressively deteriorates, manifesting as sleep fragmentation, instability of rest-activity rhythms, vulnerability of central clock structures, and loss of circadian gating of glial and clearance pathways. These disruptions create phase-inappropriate immune and metabolic states, impair protein clearance, and alter the fate of extracellular vesicles, which may shift from mediators of waste export to facilitators of proteopathic spread. Importantly, circadian failure also constrains therapeutic delivery and biomarker interpretation by modulating blood-brain barrier transport, brain fluid dynamics, and brain-to-blood signal export. We propose that AD can be reframed as a systems-level timing disorder, in which loss of temporal coherence integrates molecular pathology, glial dysfunction, clearance failure, therapeutic inefficacy, and biomarker variability. This framework highlights chrono-pharmacology, chrono-neurotherapeutics, and circadian-informed biomarkers as essential components of precision strategies for AD prevention and treatment.